-
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus Lancet Infect Dis (IF 36.4) Pub Date : 2024-08-20 Min Du, Min Liu, Ben Niu, Jue Liu
-
Oropouche fever, the mysterious threat Lancet Infect Dis (IF 36.4) Pub Date : 2024-08-08 The Lancet Infectious Diseases
-
Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone Lancet Infect Dis (IF 36.4) Pub Date : 2024-08-07 Sebastiaan J van Hal, Norelle Sherry, Geoff Coombs, Shakeel Mowlaboccus, David M Whiley, Monica M Lahra
-
Anthony Fauci: a life on page Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-29 Bipin Adhikari, Lorenz Von Seidlein
-
Recombination as an evolutionary driver of MERS-related coronavirus emergence Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Jarel Elgin Tolentino, Spyros Lytras, Jumpei Ito, Edward C Holmes, Kei Sato
-
Mortality of H5N1 human infections might be due to H5N1 virus pneumonia and could decrease by switching receptor Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Guido Granata, Lone Simonsen, Nicola Petrosillo, Eskild Petersen
-
Infectious disease surveillance update Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Genevieve Pascal
-
Rising measles cases in Europe—a threat to children Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Manjulika Das
-
Outbreaks compound Brazil's flooding disaster Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Tony Kirby
-
Gavi, the Vaccine Alliance supports rabies vaccination Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Talha Burki
-
Second malaria vaccine reaches Central African Republic Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Sanjeet Bagcchi
-
-
-
Lise Musset— studying antimalarial resistance in America Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Farooq Kazi, Ammara Mushtaq
-
Mallika Imwong—championing malaria genomics Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Udani Samarasekera
-
Naomi Lucchi—from malaria to pandemic preparedness Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Tony Kirby
-
A persistent vesiculo-pustular rash, eosinophilia, and itchy parents: think of scabies Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-24 Yana Marie Dimech MRCPCH, Eileen Clark MRCP, David Pace PhD
-
-
Artificial intelligence to transform public health in Africa Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-22 Collins Kipngetich Tanui, Nicaise Ndembi, Yenew Kebede, Sofonias Kifle Tessema
-
Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-22 Anders Björkman, Pedro Gil, Michael Alifrangis
-
The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-17 Peter J White, Trystan Leng, Dariya Nikitin, Lilith K Whittles
-
Escalating mpox epidemic in DR Congo Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-09 Alix Boisson-Walsh
-
Have we learned anything? Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-09 The Lancet Infectious Diseases
-
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-09 Francesco Branda, Massimo Ciccozzi, Fabio Scarpa
-
Preparedness for emerging epidemic threats: detection of Oropouche circulation in Cuba Lancet Infect Dis (IF 36.4) Pub Date : 2024-07-04 Maria Eugenia Toledo, Sonia Monteagudo Diaz, Tamara Montenegro Calderón, Katharina Kreppel, Eline Van Damme, Veerle Vanlerberghe
-
Modelling molecular and culture-based surveillance of tetracycline resistance in Neisseria gonorrhoeae Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-28 Kirstin I Oliveira Roster, Rachel Mittelstaedt, Jordan Reyes, Aishani V Aatresh, Yonatan H Grad
-
40 years of Helicobacter pylori Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-27 Udani Samarasekera
-
Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-27 Yu Kaku, Maximilian Stanley Yo, Jarel Elgin Tolentino, Keiya Uriu, Kaho Okumura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato
-
Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-20 Zitta Barrella Harboe, Omid Rezahosseini, Thea K Fischer
-
Profiling the SARS-CoV-2-specific T-cell response Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-20 Daryl Geers, Lennert Gommers, Ngoc H Tan, Susanne Bogers, Debbie van Baarle, Alba Grifoni, Alessandro Sette, Annemarie Boerma, Frederique Visscher, Mathilde Richard, Mathis Funk, Luca M Zaeck, P Hugo M van der Kuy, Bart L Haagmans, Marion PG Koopmans, Corine H GeurtsvanKessel, Rory D de Vries
-
Managing diarrhoea in Guatemala's Mayan communities Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-17 Bipin Adhikari
-
Getting treated for multidrug-resistant tuberculosis Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-17 Sanjeet Bagcchi
-
Poor leadership or institutional flaws? Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-17 Hollie Sherwood-Martin
-
Extreme upsurge of parvovirus B19 resulting in severe fetal morbidity and mortality Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-17 Anne Russcher, EJT (Joanne) Verweij, Paul Maurice, Jean-Marie Jouannic, Alexandra Benachi, Alexandre J Vivanti, Roland Devlieger
-
Survival analysis of patients with cholera admitted to treatment centres in Lusaka, Zambia Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-12 Nyuma Mbewe, Kelvin Mwangilwa, John Tembo, Martin P Grobusch, Nathan Kapata
-
Zoonotic infections by avian influenza virus: changing global epidemiology, investigation, and control Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-12 Mei Kang MPH, Li-Fang Wang PhD, Bo-Wen Sun BS, Wen-Bo Wan BS, Xiang Ji PhD, Guy Baele PhD, Yu-Hai Bi PhD, Marc A Suchard MD, Alexander Lai PhD, Min Zhang MD, Lin Wang PhD, Yan-Hong Zhu MSM, Lei Ma MPH, Hai-Peng Li BS, Ayidana Haerheng BS, Yang-Rui Qi BS, Rui-Lan Wang MD, Na He PhD, Prof Shuo Su PhD
Avian influenza virus continues to pose zoonotic, epizootic, and pandemic threats worldwide, as exemplified by the 2020–23 epizootics of re-emerging H5 genotype avian influenza viruses among birds and mammals and the fatal jump to humans of emerging A(H3N8) in early 2023. Future influenza pandemic threats are driven by extensive mutations and reassortments of avian influenza viruses rooted in frequent
-
-
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions Lancet Infect Dis (IF 36.4) Pub Date : 2024-06-03 Simon de Lusignan, Ting Shi, Tom Fowler, Nick Andrews, Dan Todkill, Xinchun Gu, Bernardo Meza-Torres, Chris Robertson, Aziz Sheikh
-
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-31 Nicole Bézay PhD, Laura Wagner MSc, Vera Kadlecek MSc, Michaela Obersriebnig MSc, Nina Wressnigg PhD, Romana Hochreiter PhD, Martina Schneider PhD, Katrin Dubischar MSc, Ulla Derhaschnig MD, Anton Klingler PhD, Julian Larcher-Senn PhD, Susanne Eder-Lingelbach MSc, Wolfgang Bender MD
Rising Lyme borreliosis incidence rates, potential for severe outcomes, and limitations in accurate and timely diagnosis for treatment initiation suggest the need for a preventive vaccine; however, no vaccine is currently available for human use. We performed two studies in adults to optimise the dose level and vaccination schedule for VLA15, an investigational Lyme borreliosis vaccine targeting outer
-
Vaccination hesistancy in Lyme borreliosis Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-31 Raymond J Dattwyler, Paul M Arnaboldi
-
Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-24 Ann R Falsey MD, Tessa Hosman MD, Arangassery Rosemary Bastian PhD, Sjouke Vandenberghe PhD, Eric K H Chan PhD, Macaya Douoguih MD, Esther Heijnen MD, Christy A Comeaux MD, Benoit Callendret PhD, CYPRESS investigators, Mohammed Allaw, Toby Briskin, Daniel Brune, Richard Egelhof, John Ervin, Ann Falsey, Carolos Fierro, David Fried, Peta-Gay Jackson-Booth, Murray Kimmel, Lorrie McGill, Paul Nugent, Suchet
Ad26.RSV.preF–RSV preF protein showed 80·0% vaccine efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in older adults during one RSV season. No RSV vaccines have shown three-season efficacy. We aimed to evaluate efficacy of Ad26.RSV.preF–RSV preF protein over three RSV seasons. CYPRESS was a randomised, double-blind, placebo-controlled, phase 2b study done at
-
The long-term efficacy of a respiratory syncytial virus vaccine for older adults Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-24 Charles J Sande
-
Reflecting on the cost of recurrent conflicts for the USA Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Georgia Bisbas
-
A tribute to the elimination of leprosy Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Manjulika Das
-
Managing loss during the COVID-9 pandemic Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Henrietta Dunsmuir
-
The inequity in reproductive health in Brazil Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Talha Burki
-
-
Virological characteristics of the SARS-CoV-2 KP.2 variant Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-20 Yu Kaku, Keiya Uriu, Yusuke Kosugi, Kaho Okumura, Daichi Yamasoba, Yoshifumi Uwamino, Jin Kuramochi, Kenji Sadamasu, Kazuhisa Yoshimura, Hiroyuki Asakura, Mami Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-17 Muge Cevik MD, Lindsay C Thompson MPhil, Caryn Upton MD, Valéria Cavalcanti Rolla, Mookho Malahleha MD, Blandina Mmbaga PhD, Nosipho Ngubane MD, Zamzurina Abu Bakar MD, Mohammed Rassool MD, Ebrahim Variava MD, Rodney Dawson MD, Suzanne Staples DPhil, Umesh Lalloo MD, Cheryl Louw MD, Francesca Conradie MD, Marika Eristavi MD, Anastasia Samoilova MD, Sergey N Skornyakov MD, Niyanda Elias Ntinginya PhD
The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating bacilli. Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ)
-
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-17 Guofang Deng, Liang Fu
-
Immune evasiveness of SARS-CoV-2 variants and vaccine selection Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-15 Malin Inghammar, Fredrik Kahn
-
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-15 Ida Rask Moustsen-Helms PhD, Peter Bager PhD, Tine Graakjær Larsen MD, Frederik Trier Møller PhD, Lasse Skafte Vestergaard PhD, Morten Rasmussen PhD, Christian Holm Hansen PhD, SSI-DMC Study Group, Lasse Engbo Christiansen, Sophie Gubbels, Ramona Trebbien, Casper Westergaard, Leandro Andrés Escobar-Herrera, Vithiagaran Gunalan, Aleksander Ring, Marc Bennedbæk, Nina Steenhard, Esben Mørk Hartmann, Lene
During the 2023 Danish COVID-19 vaccination campaign, an updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB.1.5 subvariant was administered. However, the rapid spread of a genetically divergent omicron BA.2.86 subvariant, JN.1, since September, 2023, poses potential challenges due to its rapid dominance and possible immune escape. Using national electronic health registry data from
-
Rapid diagnostic tests for Lassa fever: what do we aim for? Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-08 Mirjam Groger, Michael Ramharter
-
Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-08 Jelte Elsinga MD PhD, Temmy Sunyoto MD PhD, Letizia di Stefano MD, Pier Francesco Giorgetti MD, Htet Aung Kyi MD, Chiara Burzio MD, Ximena Campos Moreno MSc, Chiedozie K Ojide MD MPH, Nnennaya Ajayi MD FWACP, Richard Ewah MD FWACS, Emeka O Ogah MD FWACP, Chioma Dan-Nwafor MPH, Anthony Ahumibe MPH, Chinwe Lucia Ochu MPH, Prof Adebola Olayinka MD, Sylvie Jonckheere MD, Pascale Chaillet MSc, Michel van
Lassa fever is a viral haemorrhagic fever with few options for diagnosis and treatment; it is also under-researched with knowledge gaps on its epidemiology. A point-of-care bedside test diagnosing Lassa fever, adhering to REASSURED criteria, is not currently available but is urgently needed in west African regions with high Lassa fever burden. We aimed to assess the validity and feasibility of a rapid
-
Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-08 Dvora Joseph Davey, Alex de Voux, Lerato Hlatshwayo, Aurelie Nelson, Lisa Frigati, Kalisha Bheemraj, Nafisa Wara, Rufaro Mvududu, Landon Myer
-
Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-06 Michal Juraska PhD, Angela M Early PhD, Li Li PhD, Stephen F Schaffner PhD, Marc Lievens MSc, Akanksha Khorgade MSc, Brian Simpkins BA, Nima S Hejazi PhD, David Benkeser PhD, Qi Wang BEng, Laina D Mercer PhD, Samuel Adjei DTM, Tsiri Agbenyega PhD, Scott Anderson BS, Daniel Ansong FWACP, Dennis K Bii MPH, Patrick B Y Buabeng MB, Sean English BS, Nicholas Fitzgerald BS, Jonna Grimsby PhD, Simon K Kariuki
The first licensed malaria vaccine, RTS,S/AS01, confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy. Between Sept 28, 2017, and Sept 25, 2018, 1500 children aged 5–17 months were randomly
-
Asymptomatic parasitemia and RTS,S vaccine efficacy Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-06 Nobuko Arisue, Nirianne Marie Q Palacpac
-
Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-06 Paul C Adamson, Vu N Hieu, Pham H Nhung, DM Whiley, TM Chau
-
Shifting transmission patterns of human mpox in South Kivu, DR Congo Lancet Infect Dis (IF 36.4) Pub Date : 2024-05-01 Patrick DMC Katoto, Winters Muttamba, Esto Bahizire, Espoir Bwenge Malembaka, Henry Kyobe Bosa, Dieudonné Mwamba Kazadi, Gaston Lubambo, Freddy Belesi Siangoli, Barnabas Bakamutumaho, Misaki Wayengera, Don Jethro Mavungu Landu, Daniel Mukadi-Bamuleka, Placide Mbala, Mark Loeb, Bruce Kirenga, Jean-Jacques Muyembe-Tamfum
-
Early life respiratory syncytial virus disease—a preventable burden Lancet Infect Dis (IF 36.4) Pub Date : 2024-04-30 Cheryl Cohen, Heather J Zar